Abingworth LLP - May 13, 2021 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role: 10%+ Owner
Signature: /s/ John Heard
Stock symbol: VERA
Transactions as of: May 13, 2021
Transactions value $: $8,499,997
Form type: 4
Date filed: 5/18/2021, 06:00 PM
Previous filing: Mar 31, 2022
Next filing: Aug 27, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERA	Class A Common Stock	Conversion of derivative security		+2.19M			2.19M	May 18, 2021	See Footnote	F1, F2
transaction	VERA	Class A Common Stock	Purchase	$8.5M	+773K	+35.32%	$11.00	2.96M	May 18, 2021	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERA	Stock Option (right to buy)	Award	$0	+9.93K		$0.00	9.93K	May 13, 2021	Class A Common Stock	9.93K	$11.00	See footnotes	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.
F2	The shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3	The options (the "Options") will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. The Options were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP. Abingworth LLP provides advisory services to ABV 8. Under an agreement between Von Emster and Abingworth LLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV 8, and must exercise the Option solely upon the direction of Abingworth LLP.
F4	ABV 8 may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV 8. Abingworth LLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.